Emergent BioSolutions | EBS - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Akebia Therapeutics USD 23.53M 3.19M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 82.79M 6.13M 2025-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Coherus Biosciences USD 15M 6.26M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exelixis USD 123.02M 19.9M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Myriad Genetics USD 122.3M 6.7M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Pacira USD 91.87M 70K 2025-12
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Xoma USD 11M 2.54M 2024-06